Kura Oncology Inc

NASDAQ:KURAUnited States

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.

Contact Information

Headquarters

12730 HIGH BLUFF DRIVE, SUITE 400SAN DIEGO, CA, United States 92130

Phone

858-500-8800

Fax

302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer

Troy Wilson

Chief Operating Officer

Kathleen Ford

Chief Medical Officer

Stephen Dale

Chief Commercial Officer

Brian Powl

Chief Legal Officer, Secretary

Teresa Bair